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Abstract 
This report summarizes the results of the 3rd Joint ENCCA‑WP7, EuroSarc, EEC, PROVABES, and EURAMOS European 
Bone Sarcoma Network Meeting, which was held at the Children’s Cancer Research Institute in Vienna, Austria on 
September 24–25, 2015. The joint bone sarcoma network meetings bring together European bone sarcoma research‑
ers to present and discuss current knowledge on bone sarcoma biology, genetics, immunology, as well as results 
from preclinical investigations and clinical trials, to generate novel hypotheses for collaborative biological and clinical 
investigations. The ultimate goal is to further improve therapy and outcome in patients with bone sarcomas.
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Organization
The 3rd European bone sarcoma networking meet-
ing was held at the Children’s Cancer Research Insti-
tute in Vienna, Austria on September 24–25, 2015. It 
was organized by Stefan Bielack, Stuttgart, and Leo 
Kager, Vienna, and supported by the European Net-
work for Cancer research in Children and Adoles-
cents Work Package 7 (ENCCA-WP7, represented 
by Stefan Bielack), the EUROpean Clinical Trials in 
Rare SARComas initiative (EuroSARC, represented by 
Bass Hassan, Oxford), the European Ewing Consor-
tium (EEC, represented by Jeremy Whelan, London), 
the PROspective VAlidation of Biomarkers in Ewing 
Sarcoma network (PROVABES, represented by Uta 
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Dirksen, Münster), and the European branch of the 
EURopean and AMerican Osteosarcoma Study Group 
(EURAMOS, represented by Stefan Bielack and Jeremy 
Whelan).
High‑grade osteosarcoma
Genomics
High-grade osteosarcomas (HGOS) have complex 
karyotypes showing abundant structural and numeri-
cal aberrations. Michaela Nathrath, Kassel, presented 
data from the Cooperative Osteosarcoma Biology Study 
Group. Exomes of 31 HGOS were sequenced and their 
evolutionary landscape was deciphered by inferring 
clonality of the individual mutation events. Exome find-
ings were interpreted in the context of mutation and 
single-nucleotide polymorphism (SNP) array data from 
a replication set of 92 tumours. 14 genes were identi-
fied as the main drivers, some of which were formerly 
unknown in the context of HGOS. Tumour protein 53 
(TP53) and molecular pathways functionally similar to 
TP53 seem to drive genomic instability in HGOS. More 
than 80 % of HGOSs exhibited a specific combination of 
single base substitutions, loss of heterozygosity (LOH), 
or large-scale genome instability signatures character-
istic of breast cancer 1/2, and early onset (BRCA1/2)-
deficient tumours. The findings imply that multiple 
oncogenic pathways drive chromosomal instability dur-
ing osteosarcoma evolution and result in the acquisi-
tion of BRCA-like traits, which could be therapeutically 
exploited.
The Norwegian Sarcoma Consortium (http://NoSarC.
org), a national collaboration collecting samples from 
all sarcoma patients in Norway for next generation 
sequencing (NGS)-based analysis and the search for 
new therapies, was introduced by Ola Myklebost, Oslo. 
He presented preclinical studies of a panel of osteosar-
coma cell lines using NGS of DNA and RNA (Ref Lor-
enz et  al. PMID 26672768). They found hundreds of 
fusion transcripts, of which only a small fraction cor-
responded to fusion genes, suggesting a phenotype of 
trans-splicing, by which transcripts from different genes 
are joined during splicing. They did, however, find a 
recurrent fusion gene involving PMP22 (which encodes 
peripheral myelin protein 22) and ELOVL5 (which 
encodes ELOVL fatty acid elongase 5). Whereas only a 
few of the genomic fusions produced fusion transcripts, 
the trans-spliced mRNAs should yield large numbers 
of neoantigens that could support immune checkpoint 
therapies. Furthermore, all cell lines had completely 
abrogated the p53 response, largely caused by copy 
number-neutral fusions and aberrations of TP53. The 
group will perform the NGS analysis of the SARC028 
trial of Pembrolizumab in sarcoma.
Modulation of drug effects in osteosarcoma cells, drug 
resistance and pharmacogenomics
Given the plateau in survival over the last three dec-
ades, Anne-Marie Cleton-Jansen, Leiden, discussed new 
opportunities for HGOS therapy. Improving the efficacy 
of chemotherapy might provide one such opportunity 
and could be achieved, for example, by modulating the 
pharmacodynamic effects of drugs in HGOS cells. Using 
a small interfering RNA (siRNA) screen, the aven-ATM 
serine/threonine kinase-checkpoint kinase 1 (ATM-
CHEK1) pathway was identified as a target to sensitize 
osteosarcoma cells to conventional chemotherapeutic 
agents. Modulation of Aven-ATM-CHEK1 may also pro-
vide a novel strategy towards improving HGOS therapy.
Aurélie Dutour, Lyon, demonstrated that chemothera-
peutic treatments trigger an increase of netrin-1 (NTN1) 
expression, accompanied by an increase in netrin-1 
dependence receptors DCC and UNC5H, and that com-
bining chemotherapeutic agents and netrin-1 interfer-
ence potentiates cancer cell death. The effect of anti-Ntn1 
antibody combined with doxorubicin was investigated 
in an orthotopic metastatic rat model of osteosarcoma. 
The combination slows down osteosarcoma progression, 
significantly prolongs animal survival and prevents meta-
static dissemination. Therefore, combining conventional 
drugs with Ntn-1 interference could lead to superior 
efficacy as well as lower chemotherapy doses for HGOS 
treatment.
Blocking mammalian target of rapamycin (mTOR) 
activity is a promising approach to the treatment of 
patients with HGOS, although mTOR monotherapy has 
met with mixed results. Winette van der Graaf, London, 
suggested that combination therapy might be the key 
to success. Using two in vivo osteosarcoma models, she 
and her colleagues demonstrated that the activity of the 
mTOR-inhibitor temsirolimus is significantly enhanced 
by the addition of either cisplatin or bevacizumab. More-
over, extensive immunohistochemical and 3′-deoxy-3′-
18F-fluorothymidine positron emission tomography/
computed tomography (18F-FLT-PET/CT) analyses of 
tumour response indicated that tumour volumes under-
estimated treatment efficacy, and that 18F-FLT-PET/CT 
can potentially be used to measure response in the early 
phases of treatment. These findings suggest the need for 
further exploration of temsirolimus combined with either 
cisplatin or bevacizumab for HGOS, with the incorpora-
tion of 18F-FLT-PET scans.
Stefano Ferrari, Bologna, pointed out that novel 
approaches to the treatment of HGOS should include 
patient risk stratification. For example, over-expression 
of the ATP-binding cassette transporter B1 (ABCB1) 
at diagnosis is involved in the processes of resistance to 
classic antineoplastic drugs, identifying patients with a 
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poor prognosis in Italian sarcoma group (ISG) studies. 
The ISG and Spanish sarcoma group are presently car-
rying out a trial (ISG/OS-2, ClinicalTrials.gov number: 
NCT01459484) in which patients are stratified into dif-
ferent regimens based on ABCB1 expression. Besides 
ABCB1, overexpression of the DNA excision repair pro-
tein ‘excision repair cross-complementation group 1’ 
(ERCC1) was found to be associated with a high relapse 
rate and poor EFS and OS. The co-evaluation of ERCC1 
and ABCB1 protein expression showed that patients pos-
itive for both markers had a significantly worse prognosis.
Pharmacogenomics, which aims to tailor drug therapy 
based on the genomic ‘make-up’ of normal host cells and 
cancer cells, can help to improve drug therapy. Accordingly, 
there has been an increase in pharmacogenomic investiga-
tions in patients with HGOS. Dr. Ferrari pointed out that 
a special effort should be made to prospectively undertake 
pharmacogenetic profiling of patients entering clinical trials.
From bench to bedside, and back to bench
The beneficial effect of combining chemotherapy with 
the bisphosphonate zoledronate in syngenic models of 
rat osteosarcoma constituted the rationale for the French 
OS2006 trial (NCT00470223). Laurence Brugières, Ville-
juif, reported on the final results of the OS2006 trial con-
ducted in France between 2007 and 2014. 315 patients 
with HGOS (83  % localised and resectable) were ran-
domised to receive or not 10 injections of zoledronate 
in addition to chemotherapy. The final analysis of this 
trial showed that the addition of zoledronate to pre- and 
post-operative chemotherapy did not improve event-free 
and overall survival of patients with previously untreated 
osteosarcoma. This analysis also showed a slight excess of 
events and deaths in patients treated with zoledronate as 
compared to patients without zoledronate, leading to a 
non-significant difference in EFS and OS.
Françoise Rédini, Nantes, provided information on how 
the French group will explore the biological background 
for the unexpected results of the OS2006 trial. Several 
hypotheses have been raised which include involvement 
of infiltrating macrophages, receptor activator of nuclear 
factor-kappa B (RANK)-expressing osteosarcoma cells, 
tartrate-resistant acid phosphatase (TRAP) expressing 
cells in the tumour bone niche, and the impact of the 
hormone microenvironment. The objective of ancillary 
studies performed on OS2006 biological samples is to 
determine whether the results are linked to the disease 
itself (HGOS), to the bone microenvironment, or to the 
age of the patients.
Immunology and immunotherapy in HGOS
David Thomas, Darlinghurst, provided an overview 
of immunotherapeutic approaches, which hold great 
promise for cancer treatment. HGOS is noted to be an 
immunologically interesting disease, for multiple rea-
sons. For example, HGOS is assumed to derive from 
osteoblasts, a unique cell type that, together with the 
osteoclast, plays an important role in bone development 
and physiology. Dr. Thomas reviewed the complex signal-
ling molecules and interdependencies that link the osteo-
blast and osteoclast, and their overlap with the immune 
system. There is an association between mutational load 
and tumour neo-antigens, apparently important to the 
effectiveness of a new generation of immunotherapies 
(e.g., immune checkpoint inhibitors). In addition, HGOSs 
are noted to be genotypically complex and unstable, 
potentially making them good targets for immunothera-
pies. There is a long history of immunological approaches 
to HGOS (e.g., muramyl-tripeptide and interferons), 
which reinforces optimism about their susceptibility to 
new developments in immune therapies.
Piotr Rutkowski, Warsaw, showed that overexpression 
of programmed cell-death ligand 1 (PD-L1) on tumour 
cells, which interact with PD-1 on cytotoxic T-lympho-
cytes, impedes antitumour immunity and results in 
immune evasion. Interruption of the PD-L1/PD-1 path-
way therefore represents an attractive therapeutic strat-
egy to reinvigorate tumour-specific T cell immunity. He 
reported that PD-L1 had been observed to be signifi-
cantly expressed in different subtypes of sarcomas includ-
ing osteosarcoma (36  %), leiomyosarcoma (97  %) and 
Ewing sarcoma (39 %), while Kim et  al. detected PD-L1 
expression in 70  % of leiomyosarcomas, 67  % of Ewing 
sarcomas and 75 % of synovial sarcomas. These levels of 
expression, together with the poorer outcome of sarcoma 
patients with PD-L1 positivity, justify further exploration 
of the role of PD-L1 antibody in the treatment of sarco-
mas. Currently, the Soft Tissue and Bone Sarcoma Group 
of the European Organisation for Research and Treat-
ment of Cancer (EORTC) and several pharmaceutical 
companies are planning phase II studies of anti-PD-L1 
antibodies in advanced sarcomas, including HGOS.
The focus of the immunoSARC project, presented 
by Javier Martin-Broto, Sevilla, is to explore immu-
nomodulation as a therapeutic approach in sarcomas. 
The perspective is not only to investigate the impact of 
immune target drugs (e.g., PD-1 or PD-L1 inhibitors), 
but also to focus on the role of immunomodulation via 
combinations of these drugs with anti-angiogenic agents. 
Whereas the link between angiogenesis of tumours and 
immune evasion (e.g., via vascular endothelial growth 
factor A [VEGFA]) is well known, this connection has 
been poorly studied in sarcomas even though some 
tumours are highly vascularised. A “pick the winner” 
randomized phase II trial has been designed, compar-
ing the anti-PD-1 antibody nivolumab alone versus the 
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combination of nivolumab plus pazopanib (a multi-tar-
geted tyrosine kinase inhibitor that blocks angiogenesis) 
in cohorts of patients with bone sarcomas and soft tis-
sue sarcomas. This investigation aims to explore whether 
combination arms prove to be synergistic in efficacy in 
selected sarcoma subtypes and if some immune targets 
(e.g., PD-1/PDL-1) could be predictive at least in some 
sarcoma subtypes.
Franca Fagioli, Torino, provided preclinical data on 
two different adoptive immunotherapy strategies for 
the treatment of sarcomas, including HGOS, namely 
human leukocyte antigen (HLA)-unrestricted and HLA-
restricted strategies, with cytokine-induced killer (CIK) 
cells and sarcoma-specific cytotoxic T-lymphocytes 
(CTLs), respectively. The results of her investigations 
have provided preclinical proof-of-concept for an effec-
tive strategy to attack sarcomas with CIKs. A Phase I 
study with CIKs for patients with high-risk sarcomas, 
including HGOS, is being prepared.
Bass Hassan, Oxford, reviewed current knowledge 
on the macrophage activating drug mifamurtide in the 
context of osteosarcoma and provided an overview on 
the MEMOS (‘A mechanistic study of mifamurtide in 
patients with metastatic and/or recurrent osteosar-
coma’) trial (EudraCT Number: 2012-000615-84; http://
www.oncology.ox.ac.uk/trial/memos) of the EuroSARC 
group (http://eurosarc.eu/). The primary objective of 
this EuroSARC funded investigator initiated trial is 
to analyze biological effects of mifamurtide, and so 
requires tumour biopsies. A number of centres in UK, 
Norway, Italy and the Netherlands have begun recruit-
ing patients.
Chondrosarcoma and spindle/pleomorphic bone 
sarcomas
Judith Bovée, Leiden, provided an update on the biol-
ogy of chondrosarcoma (CS). A novel mouse model for 
peripheral CS has emphasized that, in addition to bial-
lelic inactivation of exostosin glycosyltransferase (EXT1 
or -2) in chondrocytes, additional alterations affecting 
either the TP53 or cyclin-dependent kinase inhibitor 2A 
(CDKN2A) cause malignant transformation towards sec-
ondary peripheral chondrosarcoma. It was shown that 
mutations in isocitrate dehydrogenase (IDH1 or -2) are 
an early event for central tumours: the oncometabolite 
D-2-hydroxyglutarate induced by the mutation inhibits 
osteogenic differentiation and promotes chondrogenic 
differentiation, causing enchondromas of bone. In cen-
tral chondrosarcomas, the IDH mutation is, however, 
no longer a driver mutation, as inhibition of the mutant 
protein has no effect on the tumourigenic properties 
of chondrosarcoma cell lines. Other additional genetic 
alterations are instead involved, affecting amongst others 
the TP53 and retinoblastoma (Rb) pathways, as well as 
collagen, type II, alpha 1 (COL2A1), neuroblastoma RAS 
viral oncogene homolog (NRAS), and other signalling 
pathways (e.g., hedgehog, mTOR, Bcl-2, survivin).
Jeremy Whelan, London, discussed treatment of mes-
enchymal CS, which is a very rare subtype accounting for 
approximately 5  % of chondrosarcoma. The diagnosis is 
supported by identification of a translocation involving 
the transcription factor HEY1 and the nuclear receptor 
coactivator 2 (NCOA2). It mostly affects young adults and 
can arise at multiple anatomical sites, either in soft tissue 
or bone. A recent publication by Frezza et  al. of a case 
series derived from the experience of European centres of 
excellence, has supported the prognostic significance of 
metastatic disease and proposed a survival advantage for 
the use of adjuvant chemotherapy. A second recent pub-
lication by Xu et al. using data extracted from subsets of 
patients reported in multiple retrospective series, drew 
opposite conclusions. Examples of where observational 
data had influenced clinical practice, but were refuted 
by data from randomised trials, were used to emphasize 
the importance of randomised studies, even in very rare 
sarcoma subtypes. The challenges of undertaking a ran-
domised study of chemotherapy in mesenchymal chon-
drosarcoma were described using a recently published 
typology for access to trials and were concluded to be too 
formidable.
Hans Gelderblom, Leiden, reported on the COSYMO 
Study (EudraCT No: 2013-005155-32) in which three 
cohorts of patients (i.e., conventional chondrosar-
coma, dedifferentiated/mesenchymal CS, and myxoid/
round cell liposarcoma [MLS]) are treated with a com-
bination of mTOR inhibition and cyclophosphamide. 
The rationale to use this drug combination in patients 
with CS and MLS derives from preclinical and clinical 
investigations.
Piero Picci, Bologna, stressed the importance of a more 
accurate classification for spindle/pleomorphic bone sar-
comas, as recently drawn up for soft tissue sarcomas. This 
would permit more specific chemotherapy regimens for 
the different entities within collaborative studies, made 
necessary by the rarity of these sarcomas.
Ewing sarcoma
Biology of Ewing sarcoma and Ewing‑like sarcomas
Heinrich Kovar, Vienna, reported on novel players in 
the pathogenesis of Ewing sarcoma (EwS). EWS-FLI1 
affects a number of nicotinamide adenine dinucleotide 
(NAD) metabolizing enzymes, resulting in reduction of 
NAD levels in EwS cells. Drugs, which interact with the 
NAD metabolome (e.g., nicotinamide phosphoribosyl-
transferase [NAMPT]) may be considered for preclinical 
development in EwS.
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David Herrero-Martin, Barcelona, provided data on 
non-coding RNAs in EwS. Analysis of the EwS methyl-
ome showed miR-10a (5p) hypermethylation; and miR-
10a was found to be expressed at very low levels in both 
EwS cell lines and patient samples. Reintroduction of 
miR-10a in two EwS cell lines reduced migratory capac-
ity and decreased clonogenic growth. An iTRAq (isobaric 
tags for relative and absolute quantification) proteomic 
analysis of miR-10a transfected cells allowed identifi-
cation of several proteins that could be related to the 
described phenotype.
Oscar Martinez Tirado and co-workers, Barcelona, 
revealed a role for ephrin A receptor 2 (EphA2) in the 
progression of EwS. This receptor chiefly participates in 
the migratory capacity of EwS cells by ligand-independ-
ent means. Work is in progress to decipher the molecular 
mechanisms associated with such effects.
Franck Tirode, Paris, reported that four Ewing-like 
sarcoma entities have been described as small round 
cell tumours presenting morphological characteristics 
of EwS but carrying a different chromosomal transloca-
tion (either one of BCOR-CCNB3, CIC-DUX4, EWSR1-
NFATc2 or EWSR1-PATZ1). The resemblance of these 
Ewing-like tumours, both to ES and among each other, 
was examined. It was first demonstrated that EwS present-
ing rare fusion variants such as FUS-ERG or FUS-FEV are 
transcriptionally undistinguishable from classical EWSR1-
FLI1 or EWS-ERG positive tumours. Second, expression 
profiling and careful examination of clinical and patho-
logical data indicated that the four Ewing-like sarcomas 
are far from resembling EwS and are distinct entities. 
Tirode et al. proposed to consider EwS as tumours carry-
ing only fusions involving FET family proteins (EWSR1 or 
FUS) with ETS transcription factor genes (ERG and PEA3 
types). While CIC-DUX4 and BCOR-CCNB3 are now 
classified as undifferentiated/unclassified sarcomas in the 
latest WHO sarcoma classification, said group proposed 
adding to this category all other types of Ewing-like trans-
locations, as EWSR1-NFATc2 and EWSR1-PATZ1. Finally, 
it might even be advisable to provide a different nomen-
clature for Ewing-like sarcomas such as small round cell 
sarcoma with X-X translocation.
Epigenetics, inhibition of signalling pathways 
and circulating tumour DNA in EwS
Günther Richter, Munich, reported that next-generation 
sequencing (NGS) data confirm EWS/ETS transloca-
tions as the crucial driver event of EwS tumourigenesis. 
EWS/FLI1 induces altered epigenetic marks, and target-
ing ‘epigenetic readers,’ such as bromodomain-contain-
ing proteins (e.g., BRD3/4) in EwS, reduces EWS/FLI1 
expression. Treatment with bromodomain and extra-
terminal motif (BET) inhibitors such as JQ1 blocks the 
typical expression profile of EwS. Moreover, JQ1 inhib-
its proliferation, induces apoptosis and reduces EwS 
tumour growth. When combined with phosphatidylino-
sitol-4,5-bisphosphate 3-kinase (PI3K) inhibitor BEZ235, 
inhibition of BRD3/4 may offer new opportunities for 
combination therapy in EwS.
Emmy Fleuren, Nijmegen, focused on the topic of 
multi-receptor tyrosine kinase targeting in EwS. Unfor-
tunately, inhibitors targeting a single receptor tyrosine 
kinase (RTK), such as insulin-like growth factor 1 recep-
tor (IGF-1R), have been shown to be insufficient for EwS 
treatment in clinical practice. Since research indicates 
that tumours often do not rely on a single RTK and dif-
ferent RTKs can compensate for one another to maintain 
tumour growth, Fleuren et  al. hypothesized that target-
ing multiple RTKs at once may be a more promising 
approach. They therefore investigated the co-expression 
patterns and co-targeting effects of various oncogenic 
RTKs implicated in EwS in 30 primary ES patient sam-
ples. Significant, strong positive correlations and co-
expression patterns were observed between IGF-1R 
and MET, IGF-1R and AXL, and MET and AXL recep-
tors. Co-targeting these RTKs was synergistic or at least 
additive in 6/6 EwS cell lines in  vitro, with the most 
pronounced effects in IGF-1R-targeted combinations, 
indicating that IGF-1R deserves further investigation, 
particularly in combinations.
Jenny Potratz, Münster, provided data showing that 
the receptor tyrosine kinase (RTK) ‘recepteur d’origine 
nantais’ (RON) is expressed and active in EwS, with over-
expression in tumours derived from metastatic disease. 
Evidence of function in pro-metastatic cellular features 
supports RON as a potential therapeutic target. How-
ever, targeting strategies are challenged by the isoform 
known as short-form RON which lacks the extracellular 
antibody-binding domain, thereby bypassing antibody 
inhibition. This exemplifies that isoforms, principally 
described in diverse RTKs, require attention and further 
understanding to adapt targeting strategies.
Bass Hassan discussed the rationale for dual inhibition 
of IGF-1R and insulin receptor (IR) in EwS. Moreover, he 
presented the LINES trial (http://www.oncology.ox.ac.uk/
trial/lines): a Bayesian single-arm phase II trial in which 
the dual anti-IGF-1R/IR drug linsitinib is investigated in 
patients with relapsed and/or refractory EwS. This Euro-
SARC biomarker directed study is currently recruiting 
in UK, Italy, Germany and the Netherlands, despite pro-
longed administrative and set up delays. The study incor-
porates intensive analysis including 18FDG-PET-CT and 
biopsies (pathway and gene expression responses includ-
ing RNASeq) before and after high dose linsitinib expo-
sure, and aims to discover potential mechanisms of dual 
IGF1R/IR kinase sensitivity and resistance.
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Katia Scotlandi, Bologna, reported on the interaction 
between the cytotoxic drug trabectedin (Yondelis®) and 
IGF-1 signalling. In EwS, trabectedin may not only inhibit 
but also enhance the binding of EWS-FLI1 to certain tar-
get genes, leading to upregulation of IGF1R. Combina-
tion of trabectedin and anti-IGF-1R inhibitors represents 
a potential therapeutic option for patients with EwS.
Markus Metzler, Erlangen, provided information on the 
EFACT (EWS-FLI sequence analysis from ctDNA) pro-
ject, which assesses circulating tumour DNA (ctDNA) 
as a response marker in EwS. EFACT is implemented 
as an accompanying research project to the ongoing 
EWING2008 trial. Extended application to relapsed EwS 
appears particularly informative considering that per-
sonalized treatment schedules are often necessary in this 
cohort. Analysis of ctDNA copy numbers is suited for 
integration in preclinical studies and Phase I/II trials as 
an additional response marker.
Delivering trials effectively for bone sarcoma
What can be learned from recent sarcoma trials?
Hans Gelderblom provided an overview on recently 
published clinical trials in HGOS, EwS and CS and 
discussed the difficulties in conducting investigator-
initiated clinical trials in bone sarcomas. Collabora-
tion, creation of centres of expertise for bone sarcomas, 
innovative statistical designs, lowering administrative 
burden, inventive funding, molecular tumour boards, 
etc. might help to boost investigator-initiated research 
in bone sarcomas.
Marie-Cecile LeDeley, Villejuif, summarized results 
from the EURO-EWING 99 trial (NCT00020566) and 
discussed how to make international cooperation more 
efficient, based on the experience acquired in the EURO-
EWING 99 trial.
Uta Dirksen, Münster, provided an update on the inter-
national EWING 2008 trial (NCT00987636; https://www.
clinicaltrialsregister.eu/ctr-search/trial/2008-003658-13/
DE) which is open in 11 countries and more than 100 cen-
tres. The trial includes three arms: standard risk, high risk 
and very high risk with different randomised questions. 
It is the first clinical trial to also include a randomised 
question for patients with very high risk EwS with pri-
mary disseminated disease. An interdisciplinary interna-
tional tumour board is open for patients treated within 
the clinical trial and also for patients who do not have the 
chance to receive treatment within clinical trials. Part of 
the report focused on the administrative barriers to open-
ing an investigator-initiated trial in Europe with national 
directives on top of the EU directives, and the advantages 
of a harmonized online registration and data entry system 
(MARVIN; https://www.xclinical.com/en/products/mar-
vin), now used by many European clinical trials.
The “Prospective Validation of Biomarkers in EwS for 
a personalized medicine” project (PROVABES, http://
provabes.uni-muenster.de) was also presented. Provabes 
is a joint proposal by the leading European Ewing sar-
coma study groups and basic and translational research-
ers. Aim of the study is to validate previously described 
putative predictive and prognostic biomarkers. The 
group expects that a combination of markers rather than 
a single biomarker will provide the most informative 
prognostic algorithm for patients with EwS.
A short summary was provided on the long-term fol-
low up and late effect study, PanCareLife (http://pancare-
life.eu), focusing on fertility after cancer.
Bernadette Brennan, Manchester, reported on the Euro 
Ewing 2012 trial (EudraCT Number 2012-002107-17, 
http://www.euroewing.eu/clinical-trials/ee2012-trial) 
which has been opened and recruiting patients since 
December 2013 in UK, Spain and France. Thus far, 54 
European centres are open with plans to set up centres 
in Australia and Israel in 2016. The opening of all inter-
national centres, sponsored by the Birmingham ‘Cancer 
Research UK Clinical Trial Unit’ (CRUK CTU), involving 
each country’s interpretation of EU trials regulations, has 
not been quick or easy. The CTU should perhaps have 
considered that protracted contracts with other coun-
tries would occur and have avoided the ensuing delays 
by addressing the problem much earlier. The presenta-
tion of data using the same investigational medical prod-
uct (IMP) in another bone tumour has caused concern 
among investigators and may affect recruitment. Lastly 
the ‘R3’ cohort of EwS were not included in this trial and 
every effort must now be made by EEC to rectify this, 
considering that their prognosis remains dismal.
Martin McCabe, Manchester, reported on the ‘rEE-
Cur’ trial (http://www.euroewing.eu/clinical-trials/
reecur/index), which aims to compare four commonly 
used chemotherapy regimens for efficacy and toxic-
ity in refractory and relapsed EwS. It utilises a multi-
arm, multi-stage trial design to exclude less active and/
or more toxic arms at an early stage, and will therefore 
avoid recruitment of large numbers of patients to these 
less active, more toxic chemotherapy regimens. rEECur 
represents the most extensive collaboration yet between 
European Ewing sarcoma clinical trial groups. This col-
laboration has been facilitated by the acquisition of Euro-
pean Commission funding. However, despite a keen 
willingness to collaborate and a desire to successfully 
answer the study questions, opening the study has been 
hampered by the requirement of each EU member state 
to individually interpret the EU Clinical Trials Directive 
through its Competent Authority, and to assess the ethi-
cal issues of the study. Two years into a 5-year grant, the 
study is open in six out of the planned thirteen countries. 
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None of the queries raised by Competent Authorities or 
ethics committees have yet resulted in any changes to the 
design, to implementation of the study protocol or to the 
patient consent process, but the bureaucracy required to 
repeat the process in thirteen countries has contributed 
significantly to the time and resources needed to open 
the study. Major European funders should consider this 
time delay as an inevitable component of cross-border 
European clinical trials when allocating resources for 
running international trials.
Stefano Ferrari commented on two ES trials run by 
ISG and the Scandinavian Sarcoma Group (SSG). ISG/
SSG3 (1999–2006) enrolled 300 patients with non met-
astatic EwS, and ISG/SSG4 (1999–2008) enrolled 102 
with metastatic EwS. Both protocols envisaged the use of 
high-dose chemotherapy (HDCHT) and peripheral blood 
stem cell (PBSC) support for high-risk patients (poor 
responders to induction chemotherapy or metastatic 
patients). Patients with non-metastatic EwS, responding 
poorly to induction treatment with the VACA-IE regi-
men, achieved the same probability of event-free survival 
as good responders, thanks to the addition of HDCHT. 
Surgery was the main option for local control. The use of 
postoperative radiotherapy should be provided in cases 
of inadequate surgical margins and when the histological 
response does not affect local control. Females and very 
young paediatric patients experience higher bone mar-
row toxicity. In patients with synchronous metastases 
(lung or only one bone metastasis) a 5-year overall sur-
vival rate of 50 % can be achieved with aggressive treat-
ment with HDCHT and total lung irradiation. Complete 
radiological response of lung metastases is predictive of 
survival. Post-relapse survival is very poor in recurrent 
patients in spite of intensive chemotherapy treatment 
with high-dose ifosfamide and high-dose busulfan and 
melphalan. Second complete remission is the main factor 
predicting post relapse survival. The role of HDCHT in 
this subset of patients is uncertain.
Sandra Strauss, London, reported on the Sarcoma 
Research through Collaboration SARC025/SP1 trial 
(http://sarctrials.org/SARC025), which is a collabora-
tive US/European phase I study of a combination of the 
poly(ADP-ribose) polymerase (PARP) inhibitor, Nira-
parib, with Temozolomide in EwS. Dr. Strauss com-
mented on the regulatory challenges that have arisen as 
the sponsor of the trial (the US SARC group) is not based 
in the European Economic Area (EEA). Models that may 
help to overcome such obstacles were discussed.
Stefan Bielack commented on similarities between the 
experiences of clinical osteosarcoma trialists with those 
reported in relation to Ewing sarcoma trials. He used the 
EURAMOS-1 study of the European and American Oste-
osarcoma Study Group as an example to describe how 
the multiple challenges arising during the past one and a 
half decades of Pan-European and transatlantic coopera-
tion were addressed. He emphasized the need for constant 
communication within a consortium of this size, the ben-
efits of joint training activities for site staff, the need to 
follow common predefined rules as well as to find compro-
mises where necessary. The EURAMOS consortium man-
aged to accomplish the primary objectives of its intergroup 
trial, and to use its visibility to lobby for a better European 
environment for investigator-initiated clinical trials.
Statistical issues
Joachim Gerß, Münster, commented on how statistics 
can contribute to making bone sarcoma research more 
effective. In the face of new discoveries or information 
collected in the course of a trial, the adoption of adap-
tive clinical trial designs enables flexible adjustments 
to be made, such as in sample size or target population. 
Flexible-adaptive clinical trial designs usually adhere to 
established quality criteria, as the meaning of type I error, 
in marked contrast to the completely different Bayesian 
statistical approach. The Bayesian statistical approach 
allows prior knowledge to be included, enabling the 
amount of information utilized in statistical analyses to 
be increased. The knowledge resulting from statistical 
evaluation is also outlined very clearly.
Carlo Lancia, Jakob Anninga, and Marta Fiocco, Leiden, 
discussed multi-drug regimens and dose intensity in HGOS, 
focusing on the decision-making process of dynamically 
adjusting therapy based on toxicity. Toxicity is a time-
dependent confounder since it is both a mortality risk-factor 
and a predictor of subsequent exposure to cytotoxic agents. 
In the presence of time-dependent confounders, the classi-
cal Cox model yields biased estimates of hazard ratios for 
the variables being investigated. Marginal structural Cox 
models are a possible solution to this problem.
How to construct and perform informative bone sarcoma 
trials?
Nathalie Gaspar, Villejuif, a member of the Innovative 
Therapies for Children with Cancer (ITCC) consortium, 
discussed strategies to prioritize agents for further devel-
opment in bone sarcoma. In a world where an increasing 
number of new drugs with increasingly varied mecha-
nisms of action are being developed each year, interna-
tional networks should think about strategies to prioritize 
agents for further development in bone sarcoma, along 
four axes. (1) To define appropriate drugable targets with 
relevant bone sarcoma biology at diagnosis and relapse. 
(2) To ensure strong preclinical evidence of drug efficacy 
alone and in combination in multiple bone sarcoma mod-
els, taking into account the microenvironment (bone, 
neoangiogenesis, immune system). (3) To promote drugs 
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with appropriate toxicity profiles that could be compat-
ible with relapse but mainly with first-line chemotherapy 
regimens. (4) To anticipate when to introduce the drug 
according to this mechanism of action, such as on bulky 
tumour or in minimal residual disease. Collaboration 
among clinicians and biologists but also statisticians is 
crucial, as the main objective remains to improve patient 
outcome by introducing new drugs into first-line treat-
ment of bone sarcomas at whatever age,.
Ornella Gonzato, Udine, a representative of SPAEN 
(Sarcoma Patients EuroNet; http://www.sarcoma-
patients.eu), discussed the efforts made over the last 
few years, by both the scientific and patient communi-
ties in the field of rare cancers, to allow patients access 
to promising new experimental drugs. Clinical studies on 
rare tumours, as bone sarcomas, require a significant col-
laborative network, resources and sufficient numbers of 
patients to lend statistical significance and value to study 
outcomes. As these tumours are, by definition, rare, the 
problem is the scarcity of the numbers involved. It there-
fore follows that as many patients as possible must be 
recruited. She outlined the crucial role that correct infor-
mation always plays in patient recruitment. This means 
managing information by defining what, how, where and 
by whom it should be delivered to patients, in order to 
make them aware of the nature of clinical trials and the 
benefits of participating in one of them.
Lindsey Bennister, London, a charity representative, 
stated that patients expect an appropriate trial to be sug-
gested by their clinician as part of their treatment plan. 
The National Cancer Patient Experience Survey (England, 
2014) found that only 35 % of sarcoma patients were asked 
by their clinician to participate in research. However, 64 % 
of these went on to participate, showing that patients are 
interested and willing to take part when invited to do so 
by their clinician. She provided recommendations on how 
to improve information on trials to patients. This included 
raising awareness about the importance of recommending 
trials to patients through a European campaign targeted at 
clinicians and supported by charities, patient groups and 
research networks. It also entailed setting up a one-stop 
sarcoma portal for clinical trials (in Europe), rather than 
having multiple places to search. Moreover, it was empha-
sised that clinical trials should get smarter about ‘market-
ing’ themselves in order to attract and retain participants, 
e.g., by sharing the excitement of what difference the trial 
could make in the future and clearly setting out the ben-
efits to individual patients.
In his capacity as a consumer representative, Chris-
topher Copland, York, presented a network of groups 
and individuals from across Europe (http://unite2cure.
org), calling for better treatment and better access to 
therapy for children and young people with cancer. The 
network decided to take the opportunity of Childhood 
Cancer Awareness month to build support for bringing 
about reform of Paediatric Medicines Regulations (2007). 
They set the target of collecting 1000 signatures for an 
e-petition by the end of September 2015, a goal which 
they easily exceeded. Amongst its supporters their web-
site now lists many prominent professionals and numer-
ous well-respected organisations in the field. They carried 
the initiative forward at meetings with the Cancer Drugs 
Development Forum and the European Medicines Agency.
Gilles Vassal, Villejuif, reported that the Cancer Drug 
Development Forum (CDDF), together with the Innovative 
Therapies for Children with Cancer Consortium (ITCC), 
the European Society for Paediatric Oncology (SIOPE) and 
the European Network for Cancer Research in Children 
and Adolescents (ENCCA), has created a unique Paediat-
ric Oncology Platform, involving multiple stakeholders and 
the European Commission (EC), with an urgent remit to 
improve paediatric oncology drug development.
Virtual tumour boards and transborder sarcoma therapy
Craig Gerrand, Newcastle upon Tyne, presented the UK 
‘National Ewing’s Multidisciplinary Team’, which began as 
a pilot project in 2011 and serves as a forum to discuss 
the local treatment of patients with ES of bone. The aim 
was to improve the consistency of treatment decisions 
through discussion and peer review. In the 4 years since 
its establishment, over 295 patients have been discussed 
and the concept has been proven. More work is required 
to move beyond the pilot phase if the panel is to fulfil its 
potential, and support data collection and clinical trials in 
this and possibly other sarcoma types.
Stephanie Klco-Brosius, and Uta Dirksen Münster, 
presented the international interdisciplinary virtual EwS 
tumour board, which has been set up in Münster as an 
ENCCA project. Eight European and international coun-
tries discuss their patients in the virtual tumour board. A 
retrospective analysis was presented of the value of a ref-
erence tumour board, implicating major advantages for 
patients with primary disseminated disease.
Ruth Ladenstein, Vienna, reported on the European 
Expert Paediatric Oncology Reference Network for Diag-
nostics and Treatment (ExPO-r-Net) (http://www.expor-
net.eu). The main aim of ExPO-r-Net is to address and 
improve health inequalities for children with cancer in 
Europe by building a European Reference Network for 
Paediatric Oncology.
Conclusion
Bone sarcomas are ultra orphan-diseases with three 
decades of stagnation in survival. To further improve 
outcomes, it is essential to promote international col-
laboration propelled by initiatives like the European Bone 
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Sarcoma Network. Novel insights from basic and clinical 
research that may help to improve sarcoma therapy were 
discussed during the meeting and results were presented 
from investigations on tumour cell genomics, epigenet-
ics, metabolism, altered signalling pathways, sarcoma 
immunology as well as on pharmacodynamics, pharma-
cogenomics, and the measurement of circulating tumour 
DNA. Moreover, experiences from recent sarcoma trials 
were reviewed and the viewpoints of patient and parent 
advocates, clinical researchers, statisticians and char-
ity representatives were summarized in order to provide 
knowledge that can facilitate the design of future clinical 
sarcoma trials. The discussions generated many novel, 
exciting ideas, which now need to be taken forward 
to proposals for innovative trials, which are urgently 
needed. Such proposals for collaborative research and 
trials should be a major focus for the next European Bone 
Sarcoma Networking Meeting, scheduled to take place in 
London in 2017.
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